Cidara Therapeutics, INC Schedule 13G passive stakes

Vivo Opportunity entities report zero beneficial ownership in Cidara Therapeutics, Inc. following the completion of a merger on January 7, 2026.

The Vanguard Group has reported a 6.38% beneficial ownership stake in Cidara Therapeutics Inc., holding over 2 million shares of common stock.

Commodore Capital LP and its affiliates have reported a 2.0% beneficial ownership stake in Cidara Therapeutics, Inc., totaling 585,000 shares of common stock.

Paradigm BioCapital Advisors LP and related entities have reported a 3.3% beneficial ownership stake in Cidara Therapeutics, Inc. as of September 30, 2025.

BCLS Fund III Investments, LP, an affiliate of Bain Capital, has reported a 9.99% beneficial ownership stake in Cidara Therapeutics, Inc. as of September 30, 2025.

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have filed an amended Schedule 13G, reporting zero beneficial ownership in Cidara Therapeutics, Inc. common stock.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 6.2% beneficial ownership stake in Cidara Therapeutics, Inc. as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 4.6% in Cidara Therapeutics, Inc. common stock.

Biotechnology Value Fund and its affiliates have reported a reduction in their beneficial ownership of Cidara Therapeutics, Inc. common stock to 4.4%, falling below the 5% threshold.

BVF Partners and affiliated entities report a combined 5.2% beneficial ownership in Cidara Therapeutics, Inc. as of September 30, 2025.

A group of Venrock entities and individuals filed an amended Schedule 13G, disclosing a continued beneficial ownership of 3.2% in Cidara Therapeutics, Inc.

Point72 Asset Management, along with its affiliates and Steven A. Cohen, reported a 7.6% beneficial ownership stake in Cidara Therapeutics, Inc. common stock.

Canaan XII L.P. and Canaan Partners XII LLC have fully divested their beneficial ownership in Cidara Therapeutics, Inc., holding 0% of common stock as of June 30, 2025.

BCLS Fund III Investments, LP has disclosed a 9.99% beneficial ownership stake in Cidara Therapeutics, Inc., comprising common and convertible preferred stock.

Vivo Opportunity Fund Holdings and affiliates updated their passive stake in Cidara Therapeutics, Inc. to 4.6% of common stock.

Adage Capital Management, L.P. and its principals have disclosed a 4.97% beneficial ownership stake in Cidara Therapeutics, Inc., holding 1,100,000 shares.

Paradigm BioCapital Advisors LP and its affiliates have reported a passive beneficial ownership of 5.6% in Cidara Therapeutics, Inc.'s common stock.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.5% beneficial ownership stake in Cidara Therapeutics, Inc. as of June 30, 2025.

Commodore Capital LP and its affiliates have reported a passive beneficial ownership of 5.5% of Cidara Therapeutics, Inc.'s common stock.

An amended Schedule 13G filing reveals that Venrock Healthcare Capital Partners and its affiliated entities collectively hold a 9.9% beneficial ownership stake in Cidara Therapeutics, Inc. as of March 31, 2025.

A group of investment funds led by Biotechnology Value Fund, L.P. has filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.99% in Cidara Therapeutics, Inc. as of March 31, 2025.

Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity, LLC, Vivo Opportunity Cayman Fund, L.P., and Vivo Opportunity Cayman, LLC have jointly filed an amendment to their Schedule 13G, disclosing a combined beneficial ownership of approximately 5.3% of Cidara Therapeutics, Inc.'s common stock as of March 31, 2025.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a 9.04% beneficial ownership stake in Cidara Therapeutics, Inc. as of March 31, 2025.

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have jointly disclosed a passive beneficial ownership of 9.1% in Cidara Therapeutics, Inc., totaling 999,414 shares.

Multiple entities associated with Biotechnology Value Fund have filed an amended Schedule 13G, revealing an aggregate beneficial ownership of 9.99% in Cidara Therapeutics, Inc. as of December 31, 2024.